The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
Texas MPN Workshop 2022 | Insights into the diagnosis and prognosis of CMML
Eric Padron, MD, H. Lee Moffitt Cancer Center, Tampa, FL, shares some insights into the diagnosis and prognosis of chronic myelomonocytic leukemia (CMML), and the challenges associated with these. Dr Padron first highlights some important factors to consider when diagnosing patients, and then discusses the need for new treatments. To conclude, Dr Padron comments on the role of stem cell transplantation (SCT) and when to consider patients for SCT. This interview took place at the third annual Texas MPN Workshop (TMW) 2022, held in San Antonio, TX.
Disclosures
Research Funding: Kura, Incyte, BMS
Honoraria: Blueprint, Novartis, Stem line, Taiho, Pharmaessentia
